Antitumor activity of TAK-243. (A) Xenografts based on either MM1.S (left panel) or MOLP-8 cells (right) were treated with either vehicle, or TAK-243 at a dose of either 12.5 mg/kg given twice weekly (BIW), or 25 mg/kg given once weekly (QW), and growth of subcutaneous tumors was monitored. (B) Expression levels of selected proteins of interest were determined by western blotting of dissected tumor tissues at the indicated time points after TAK-243 treatment. (C) Immunohistochemistry was also performed for selected proteins in tumor tissue in a separate cohort of mice from 1 to 24 hours after 1 dose treatment of TAK-243, and compared to vehicle-treated controls at 24 hours (hatched bars at left). PARP, poly-(ADP-ribose) polymerase.